Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolaños‐Meade(Johns Hopkins University), Ran Reshef(Columbia University Irving Medical Center), Raphael Fraser(Medical College of Wisconsin), Mingwei Fei(Medical College of Wisconsin), Sunil Abhyankar(University of Kansas Medical Center), Zaid Al‐Kadhimi(Emory University), Amin M. Alousi(The University of Texas MD Anderson Cancer Center), Joseph H. Antin(Dana-Farber Cancer Institute), Sally Arai(Stanford University), Kate Bickett(Emmes (United States)), Yi‐Bin Chen(Massachusetts General Hospital), Lloyd E. Damon(University of California, San Francisco), Yvonne A. Efebera(The Ohio State University), Nancy L. Geller(National Institutes of Health), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Parameswaran Hari(Medical College of Wisconsin), Shernan G. Holtan(University of Minnesota), Mary M. Horowitz(Medical College of Wisconsin), David A. Jacobsohn(Children's National), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Jane L. Liesveld(University of Rochester), Brent R. Logan(Medical College of Wisconsin), Margaret L. MacMillan(University of Minnesota), Marco Mielcarek(Fred Hutch Cancer Center), Pierre Noël(WinnMed), Joseph Pidala(Moffitt Cancer Center), David Porter(University of Pennsylvania), Iskra Pusic(Washington University in St. Louis), Ronald Sobecks(Cleveland Clinic), Scott R. Solomon(Northside Hospital), Daniel J. Weisdorf(University of Minnesota), Juan Wu(Emmes (United States)), Marcelo C. Pasquini(Medical College of Wisconsin), John Koreth(Dana-Farber Cancer Institute)
Cited by 279
Abstract
Related Papers
No related papers found
Powered by citation graph analysis